Company Overview
| Stock Name | Jenscare-B |
|---|---|
| Stock Code | 09877 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家立足中國的醫療器械公司,致力於開發用於治療結構性心臟病的介入產品。公司已開發出針對不同類型結構性心臟病(包括三尖瓣疾病、主動脈瓣疾病、二尖瓣疾病及心力衰竭)的一系列治療解決方案。 |
| Listing Date | 2022-10-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 浙江省寧波市杭州灣新區濱海四路777號B區5號樓 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | jenscare.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 27.80 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1 shares |
| Entry Threshold | HK$ 27 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2022-09-23 to 2022-09-29 |
| Global Offering Shares | 8,076,400 shares |
| HK Public Offer Shares (Initial) | 808,000 shares (10.0%) |
| Public Offer Lots (Initial) | 808,000lots (Pool A404,000lots,Pool B404,000lots) |
| International Placing Shares (Initial) | 7,268,400 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 417,167,290 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 69.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 224,523,920 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1 | HK$ 28 |
| 200 lots | 200 | HK$ 5,560 |
| 400 lots | 400 | HK$ 11,120 |
| 600 lots | 600 | HK$ 16,680 |
| 800 lots | 800 | HK$ 22,240 |
| 1,000 lots | 1,000 | HK$ 27,800 |
| 1,200 lots | 1,200 | HK$ 33,360 |
| 1,294 lots | 1,294 | HK$ 35,973 |
| 1,400 lots | 1,400 | HK$ 38,920 |
| 1,600 lots | 1,600 | HK$ 44,480 |
| 1,800 lots | 1,800 | HK$ 50,040 |
| 2,000 lots | 2,000 | HK$ 55,600 |
| 3,000 lots | 3,000 | HK$ 83,400 |
| 4,000 lots | 4,000 | HK$ 111,200 |
| 5,000 lots | 5,000 | HK$ 139,000 |
| 6,000 lots | 6,000 | HK$ 166,800 |
| 7,000 lots | 7,000 | HK$ 194,600 |
| 8,000 lots | 8,000 | HK$ 222,400 |
| 10,000 lots | 10,000 | HK$ 278,000 |
| 50,000 lots | 50,000 | HK$ 1,390,000 |
| 160,000 lots | 160,000 | HK$ 4,448,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 404,000 lots | 404,000 | HK$ 11,231,200 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.37B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +309% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 11,597,250,662 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 3,658,219,569 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损人民币500.7百万元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Other income and gains, net | 3,070 | 8,910 | 38,346 |
| Administrative expenses | -131,476 | -238,506 | -40,534 |
| Net finance costs | -594 | -130 | -50 |
| Share of associates and JVs | 0 | 1,343 | 13,549 |
| Profit before tax | -299,673 | -500,673 | -73,529 |
| Income tax expense | 0 | 0 | 0 |
| Profit for the year | -299,673 | -500,673 | -73,529 |
| Profit attributable to owners | -299,447 | -500,517 | -72,853 |
Balance Sheet
| Item | 2020 | 2021 | 2022-06 |
|---|---|---|---|
| Cash and cash equivalents | 349,067 | 800,590 | |
| Inventories | 1,520 | 4,672 | |
| Total current assets | 355,186 | 828,805 | |
| Total assets | 372,843 | 1,341,359 | |
| Total current liabilities | 18,356 | 49,700 | |
| Total liabilities | 20,060 | 50,768 | |
| Total equity | 352,783 | 1,290,591 | |
| Equity attributable to owners | 352,783 | 1,290,747 | |
| Interest-bearing borrowings | 611 | 0 | 0 |
Cash Flow Statement
| Item | 2020 | 2021 | 2022-06 | 2022 |
|---|---|---|---|---|
| Net cash from operating activities | -46,853 | -141,894 | -58,018 | |
| Net cash from investing activities | 6,619 | -475,073 | -372,006 | |
| Net cash from financing activities | 383,514 | 1,075,326 | -431 | |
| Net increase in cash | 343,280 | 458,359 | -430,455 | |
| Depreciation of PP&E | 2,444 | 3,407 | 2,754 | |
| Depreciation of right-of-use assets | 885 | 1,704 | 1,173 | |
| Amortisation of intangible assets | 13 | 150 | 146 | |
| Purchase of PP&E | -2,092 | -13,278 | -12,699 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 28.25 |
|---|---|
| First Day Open | HK$ 28.0 |
| First Day Change | 1.62% |
| First Day Volume | 1466000.0 |
| First Day Turnover | 41947900.0 |
| Use of Proceeds | 1、約65.0%或約100.6百萬港元將分配予我們核心產品(即LuX-Valve及KenValve)的研發、制造及商業化;
2、約25.0%或約38.7百萬港元將分配予產品管線的其他在研產品(包括LuXValve Plus、KenFlex及二尖瓣產品)的研發、臨床試驗及產品注冊;
3、約10.0%或約15.5百萬港元將用于營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (4)
Joint Bookrunners (7)
Joint Lead Managers (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Citigroup Global Markets Asia Limited CE AAA137
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
农银国际证券有限公司 CE ACX411
交银国际证券有限公司 CE APJ121
富途证券国际(香港)有限公司 CE AZT137
老虎证券(香港)环球有限公司 CE BMU940
SILVERBRICKS SECURITIES COMPANY LIMITED CE BLN458
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 先健科技公司 | 156,975,480 HKD | — | 69.91% | — | 6 months | 2023-04-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 呂世文 | — |
| Company Secretary | 李遠源 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股东为吕世文先生与李女士(一致行动人),合计持有本公司约50.53%股份。其他主要股东包括宁波迪翔、上海仕地、海南脉迪、宁波桑迪、宁波沐康、宁波麟灃等员工持股平台,以及高瓴资本、AUT-VII HK Holdings Limited等机构投资者。 |
|---|




